Patents by Inventor Valerian Kagan
Valerian Kagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002350Abstract: Disclosed are compounds and methods for preventing or treating necroinflammation associated with ferroptotic processes. The method includes inhibiting 15 lipoxygenase/phosphatidylethanolamine binding protein (15LOX/PEBP1) complex, wherein the inhibitor exhibits a higher binding affinity or binding activity for 15LOX/PEBP1 complex compared to 15LOX alone. Necroinflammation associated with ferroptotic processes causes several pathogenic conditions including upper or lower respiratory disorders, acute or chronic brain injury, renal injury, injury by radiation, neurodegenerative disorder, among others. The disclosed compounds and methods are useful in subjects diagnosed with one or more of these conditions.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Inventors: Sally Ellen MORGANROTH, Valerian KAGAN, Jinming ZHAO, Ganesha RAI, Hulya BAYIR, Yulia TYURINA, Haider DAR, Tamil ANTHONYMUTHU, Joel GREENBERGER, Michael EPPERLY, Diane LUCI, Juan MARUGAN, Anton SIMEONOV, Alexey V. ZAKHAROV, Adam YASGAR, Andrew AMOSCATO
-
Patent number: 10596197Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.Type: GrantFiled: June 1, 2018Date of Patent: March 24, 2020Assignee: University of Pittburgh—Of the Commonwealth System of Higher EducationInventors: Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
-
Publication number: 20180271909Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.Type: ApplicationFiled: June 1, 2018Publication date: September 27, 2018Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
-
Patent number: 10004764Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.Type: GrantFiled: November 6, 2014Date of Patent: June 26, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
-
Publication number: 20160263156Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.Type: ApplicationFiled: November 6, 2014Publication date: September 15, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Janet S. Lee, Timothy E. Corcoran, Valerian Kagan
-
Patent number: 9402839Abstract: The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the ?-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.Type: GrantFiled: February 11, 2015Date of Patent: August 2, 2016Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian Kagan, Yulia Tyurina, Anthony J. Kanai
-
Publication number: 20150297578Abstract: The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the ?-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.Type: ApplicationFiled: February 11, 2015Publication date: October 22, 2015Inventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian Kagan, Yulia Tyurina, Anthony J. Kanai
-
Patent number: 9006186Abstract: The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargoes which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the ?-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient.Type: GrantFiled: October 21, 2013Date of Patent: April 14, 2015Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Peter Wipf, Jingbo Xiao, Mitchell P. Fink, Valerian Kagan, Yulia Tyurina, Anthony J. Kanai
-
Patent number: 8883852Abstract: Provided herein are methods, for reducing, preventing, mitigating and treating damage caused by radiation. The methods comprise delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation or to mitigate apoptosis. The compounds comprise glyburide or other sulfonylurea hypoglycemic compounds or potassium channel inhibitors.Type: GrantFiled: October 21, 2009Date of Patent: November 11, 2014Assignee: University of Pittburgh—Of the Commonwealth System of Higher EducationInventors: Michael Epperly, Joel Greenberger, Jianfei Jiang, Valerian Kagan, John Lazo, Peter McDonald
-
Patent number: 8822541Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.Type: GrantFiled: January 14, 2011Date of Patent: September 2, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Peter Wipf, Natalia A. Belikova, Jianfei Jiang, Joshua Pierce, Joel Greenberger, Michael Epperly, Valerian Kagan
-
Publication number: 20110288178Abstract: Provided herein are methods, for reducing, preventing, mitigating and treating damage caused by radiation. The methods comprise delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation or to mitigate apoptosis. The compounds comprise glyburide or other sulfonylurea hypoglycemic compounds or potassium channel inhibitors.Type: ApplicationFiled: October 21, 2009Publication date: November 24, 2011Inventors: Michael Epperly, Joel Greenberger, Jianfei Jiang, Valerian Kagan, John Lazo, Peter McDonald
-
Publication number: 20110172214Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.Type: ApplicationFiled: January 14, 2011Publication date: July 14, 2011Inventors: Peter Wipf, Natalia A. Belikova, Jianfei Jiang, Joshua Pierce, Joel Greenberger, Michael Epperly, Valerian Kagan